A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)

Silvia Marcé, Montserrat Cortés, Lurdes Zamora, Marta Cabezón, Javier Grau, Fuensanta Millá, Evarist Feliu

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

© 2015 Elsevier Inc. Tyrosine kinase inhibitors (TKI) have improved the management of patients with chronic myeloid leukemia (CML). However, a significant proportion of patients does not achieve the optimal response or are resistant to TKI. ABL1 kinase domain mutations have been extensively implicated in the pathogenesis of TKI resistance. Although deletion or insertion of nucleotides in BCR-ABL1 has rarely been described, we identified a CML patient with an already described 35 nucleotides insertion (. BCR-ABL135INS) of controversial significance, that confers resistance to imatinib but sensitivity to dasatinib.
Original languageEnglish
Pages (from-to)16-18
JournalExperimental and Molecular Pathology
Volume99
Issue number1
DOIs
Publication statusPublished - 1 Aug 2015

Keywords

  • BCR-ABL1
  • CML
  • Insertion
  • Mutation
  • Resistance
  • TKI

Fingerprint Dive into the research topics of 'A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)'. Together they form a unique fingerprint.

Cite this